Business  
/
 
Sectors  
/
 
Health & Pharma
One More Thing: May brings little cheer for Pfizer staff

Elan retains a royalty interest after selling its ownership of Tysabri to partner Biogen Idec for $3.25 billion. Elan urges shareholders to reject Royalty Pharma offer

Company says bid fails to properly value business

The Pfizer plant in Ringaskiddy: while yesterday’s announcement is good news, bolstering its production, it too is an old plant. Photograph: Provision Little hope for Little Island?

Cantillon: Success in selling redundant sites hides deeper shift in Irish pharma outlook

Ken Kelleher, chairman of the Little Island Community Association, outside Pfizer’s plant in Little Island, Cork, today. Photograph: Provision Pfizer announces closure of Little Island plant

Company cites falling demand for products as patents expire

Pfizer to close Little Island plant in Cork

Manufacturing moving to Ringaskiddy facility, says company

Economist Colm Mc Carthy, with Aviva Health Insurance chief executive Alison Burns, at the launch of his report on the future of the private health market, commissioned by Aviva. Colm McCarthy opposes private patient charge plan

Economist warns of 25 per cent rise in premiums if charges imposed in public hospitals

Elan chief executive Kelly Martin. The company has agreed a $1bn royalty deal with Theravance. Photo: Alan Betson/The Irish Times Elan to pay $1bn for Theravance stake

Irish pharmaceutical company agrees to buy 21% of royalty Theravance receives from GSK

Jazz shares hit a bad note

Fears over generic competition worry investors

Liam Fitzgerald chief executive United Drug. Photograph: Cyril Byrne/Irish Times United Drug’s profit boosted by recent acquisition

Company posts pre-tax profit of €38 million for six months to March 31st

Brian O'Donoghue, CEO of Virginia Medical Supplies Inside Track:

Pharmacist creating an alternative to antibiotics for CF patients

Baxter Alzheimer’s treatment fails late-stage study

Blocking the immune system aims to improve kidney transplants success rate

Opsona Therapeutics tests immune-dampening to ward of dangerous inflamation after transplants. Claire O’Connell finds out about the science behind it

Health Pharma

Elan retains a royalty interest after selling its ownership of Tysabri to partner Biogen Idec for $3.25 billion. Elan urges shareholders to reject Royalty Pharma offer
Ken Kelleher, chairman of the Little Island Community Association, outside Pfizer’s plant in Little Island, Cork, today. Photograph: Provision Pfizer announces closure of Little Island plant
Pfizer to close Little Island plant in Cork